基金公司拟向玮俊生物科技(00660.HK)投资11.6亿元
玮俊生物科技(00660.HK)公布,公司与GEM Global Yield LLC SCS订立一不具法律约束力之投资条款书。据此,GEM基金公司有意以股份认购投资於玮俊生物科技。总融资额为11.63亿元。倘落实正式协议,公司将适时遵守上市规则之相关适用规定。
GEM基金公司是一个拥有34亿美元资产的另类投资集团,管理着针对全球新兴市场的各种投资工具。集团认为,GEM基金公司融资意向将为集团提供资金以寻找相关新冠状病毒疫苗项目投资机会。此外,如果双方之间达成正式协议,GEM基金公司将成为集团的战略投资夥伴。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.